Georgia Marie Beasley

About

Georgia Marie Beasley is an Associate Professor of Surgery and an Associate Professor in Medicine at Duke University. She is a member of the Duke Cancer Institute and is based in Durham, North Carolina. Her professional roles involve contributions to the fields of surgery and medicine, with a focus on cancer research. She is affiliated with the Duke Department of Surgery and is involved in academic and clinical activities related to biostatistics and bioinformatics, contributing to the university's research and educational missions.

Research topics

• Cancer research
• Biology
• Medicine
• Immunology
• Oncology
• Internal medicine
• Cell biology
• Computer Science
• World Wide Web
• Biochemistry

Selected publications

• Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

  Journal for ImmunoTherapy of Cancer · 2021 · 79 citations

  1st authorCorresponding

  BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following cell entry via the poliovirus receptor CD155, which is expressed on tumor and antigen-presenting cells. Preclinical studies show that oncolytic virus plus anti-PD-1 therapy leads to a greate…

  PublisherOA PDFDOI

• Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

  Nature Communications · 2021 · 72 citations

  Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly activating innate immunity. Here, we report that recombinant poliovirus therapy primarily mediates antitumor immunotherapy via direct infection of non-malignant tumor microenvironment (TME) cells, independent of malignant cell lysis. Relative to other innate immune agonists, virotherapy provokes selective, TBK1-IRF3 driven innate inflammation tha…

  DOI

• Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma

  Journal for ImmunoTherapy of Cancer · 2022 · 42 citations

  1st authorCorresponding

  BACKGROUND: We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also received anti-PD-1 after lerapolturev. In preclinical models lerapolturev induces intratumoral innate inflammation that engages antitumor T cells. In the current study, prelerapolturev and postlerapolturev tumor biopsies and blood were evaluated…

  PublisherOA PDFDOI

• RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)

  Journal of Clinical Oncology · 2025-07-08 · 30 citations

  articleOpen access

  PURPOSE Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1–based oncolytic immunotherapy, here evaluated in combination with nivolumab in anti–PD-1–failed melanoma. METHODS Patients had advanced melanoma that had confirmed progression on anti–PD-1 (≥8 weeks, last prior treatment). RP1 was administered intratumorally (≤8 doses, ≤10 mL/dose; additional doses allowed) with nivolumab (≤2 year…

  PublisherDOI

• Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status

  JAMA Surgery · 2025-10-22 · 9 citations

  articleOpen access

  Importance: Contemporary guidelines recommend sentinel lymph node biopsy (SLNB) for patients with melanoma with predicted risk of SLN metastasis greater than 10% and consideration of SLNB when the risk is 5% to 10%. A gene expression profile (GEP)-based test that can accurately identify patients with a low risk of SLN metastasis would refine selection for SLNB. Objective: To establish the predictive capability of the combined clinicopathological factors and GEP (CP-GEP) test to identify patients…

  PublisherOA PDFDOI

Recent grants

• PVSRIPO in melanoma

  NIH · $794k · 2020–2025

• PVSRIPO in melanoma

  NIH · $251k · 2020–2025

Frequent coauthors

• Douglas S. Tyler

  Kuwait Petroleum Corporation (Kuwait)

  140 shared

• Jonathan S. Zager

  Moffitt Cancer Center

  71 shared

• Christina K. Augustine

  Durham VA Medical Center

  58 shared

• April K.S. Salama

  Duke Medical Center

  55 shared

• Brent A. Hanks

  Duke University

  49 shared

• Paul J. Mosca

  Duke Medical Center

  46 shared

• James C. Padussis

  University of Nebraska Medical Center

  43 shared

• Kristen E. Rhodin

  Duke Medical Center

  38 shared

Education

• surgical oncology fellowship

  Ohio State University Hospital

  2017

• general surgery residnecy, Surgery

  Duke University Hospital

  2015

• MHSc

  Duke University School of Medicine

  2012

• MD

  Duke University School of Medicine

  2008

• BA

  Duke University

  2001

Similar researchers at Duke University

• Avshalom Caspih-242
• Allison Elizabeth Ashley-Kochh-86
• Huiman Xie Barnharth-75